The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Table 1

Study characteristics of the previously treated subgroups within included studies.

Study	LONESTAR [8]	ELECTRON [9]	ION2 [5]	Mizokami et al. [10]
Publication year	2014	2014	2014	2015
Sample size of previously treated subjects given 12 weeks of therapy	40	19	220	175
Cirrhosis	55%	100%	20%	29%
Geographical location	USA	New Zealand	USA	Japan
Funding source	Industry	Industry	Industry	Industry
Number lost to follow-up	0	0	0	0
Average age (years)	53	59	57	35% > age 65
Male gender	73%	95%	66%	43%
Genotype 1a	86%	81%	79%	4%
Genotype 1b	14%	19%	21%	96%
Black race	10%	0%	18%	0%
Mean BMI (Kg/m^2)	31.5	29.2	29	62% < 25 Kg/m^2
Mean HCV RNA ()	6.3	6.4	6.5	87% > 800,000 IU/mL